Catalyst Pharmaceuticals completes acquisition by Angelini Pharma, delisting from Nasdaq
Catalyst Pharmaceuticals completed its acquisition by Angelini Pharma and Angelini Cielo Inc. on July 15, 2026, becoming a wholly owned subsidiary of the acquirer. The company's common stock was halted from trading on Nasdaq effective after-hours on July 14, 2026, and the company notified Nasdaq of its intent to remove all shares from listing and requested filing of a Form 25 notification of removal. Trading suspension took effect on July 16, 2026, and the company intends to file a Form 15 to terminate SEC registration.
Key facts
- Merger agreement dated May 6, 2026, by and among Catalyst Pharmaceuticals, Inc., Angelini Pharma S.p.A. and Angelini Cielo Inc.
- Merger consummated July 15, 2026; Catalyst became wholly owned subsidiary of Parent
- Each share of Company Common Stock converted into right to receive Merger Consideration at Effective Time
- All seven directors resigned as of Effective Time: Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; David S. Tierney, M.D.
- Directors of Merger Sub became directors of Surviving Corporation: Sergio Marullo di Condojanni; Massimo Marin; Enrica Dogali
- Company Common Stock halted from trading on Nasdaq after-hours July 14, 2026
- Form 25 notification of removal filed with SEC to delist and deregister Company Common Stock
- Form 15 to be filed requesting termination of registration under Section 12(g) of Exchange Act
Why it matters
The transaction transfers control of the pharmaceutical company to Italian-based Angelini Pharma, removes Catalyst from public markets, and terminates the company's SEC reporting obligations.
Developing story
- 25-NSE
- 8-Kthis filing
Share
Derived from 8-K filed 2026-07-16. Not investment advice. View the source filing on SEC.gov →